TradeFlare's AI research teams analysed TYRA on 6 market nights between April 13, 2026 and April 22, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| April 22, 2026 | BUY | $36.69 | — / — | -9.5% | -10.6% | Positive clinical trial results for dabogratinib. |
| April 20, 2026 | HOLD | $35.56 | — / $30.11 | +7.4% | +3.8% | Analyst upgrades |
| April 17, 2026 | HOLD | $35.12 | $37.63 / $30.11 | +5.7% | +4.2% | To allow time for the stock to potentially break through resistance, while acknowledging the conflicting signals and high risk. |
| April 15, 2026 | HOLD | $35.27 | $37.65 / $33.95 | +6.8% | +3.5% | To allow time for the price to potentially break through resistance or reverse. |
| April 14, 2026 | HOLD | $35.62 | $50.96 / $33.92 | +4.0% | -1.1% | The fundamental analysis suggests a long-term upside based on clinical trial progress and analyst price targets. |
| April 13, 2026 | BUY | $35.26 | $37.71 / $33.88 | -3.5% | -4.5% | Technical analysis suggests a short-term breakout opportunity. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.